SecBot SecBot
144 ·Filed Nov 3, 2026

INSM

INSMED Inc
NEUTRAL
Impact 2/10
Horizonimmediate Processed13d 6h ago SEC0001628280-26-069586
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale by a former officer, not a discretionary insider sale. No material impact on the stock is expected. Monitor for any subsequent Form 4 filings to confirm the sale was executed.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$110.00
T+0 close · Nov 3, 2026 · via day close
Latest settled
+9.77%
T+5 · $120.75 · next T+20 in 16d
Vs SPY
+10.69%
α at T+5
Latest observation
+11.03%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $110.00entry
  2. T+1 · 12d ago −1.13%α +3.28% · $108.76
  3. T+5 · 6d ago +9.77%α +10.69% · $120.75
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sara Bonstein, a former officer of Insmed, filed a Form 144 notice of intent to sell 10,261 shares of common stock. The sale is to satisfy tax withholding obligations upon vesting of restricted stock units and related broker fees, indicating a routine, non-discretionary sale rather than a directional signal.

Key Facts

  • Filer: Sara Bonstein, a former officer of Insmed Inc.
  • Shares to be sold: 10,261 shares of common stock.
  • Reason: Shares sold to satisfy tax withholding obligations upon vesting of Restricted Stock Units and to cover related broker fees.
  • Date of proposed sale: November 3, 2026.
  • Market cap of Insmed: $24.4 billion.

Financial Impact

10,261 shares; at the company's market cap of $24.4B, this represents a negligible fraction of outstanding shares.

dilution

Risk Factors

  • None material; the sale is mandatory and non-discretionary.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-069586
Document: 0001628280-26-069586-index.html0001628280-26-069586
Document: 0001628280-26-069586.txt0001628280-26-069586

Track record

24 reports on INSM

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago 144 Neutral 2/10 Viewing Entry $110.00 Now $122.88 +11.71% settles Dec 3
  2. Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
  4. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
  6. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
  8. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
  9. Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
  10. Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (9h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026